ZOTANSEZota Health Care LImitedMinimalNeutral
Announced Fri, 22 May · 19:58 IST

Zota Health Care Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Audited Financial Results for the quarter and year ended March 31, 2026".

ZOTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹1190.00
prior close
₹1190.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+1.8+0.9-1.9-1.7-5.6-5.9-5.5-4.5-0.3+2.2+16.7+8.2
Up moveDown movePending
AI summary

Zota Health Care Limited reported strong FY26 results with consolidated revenue of ₹53,865.75 lakhs, up 83.86% YoY from ₹29,297.46 lakhs in FY25. Gross profit grew 108.57% to ₹32,468.90 lakhs with gross margin expanding by 714 basis points to 60.28%. The company turned EBITDA positive at ₹2,597.73 lakhs compared to a loss of ₹366.51 lakhs last year. The Davaindia pharmacy chain expanded to 2,579 stores nationwide, adding 997 new stores during the year, making it the highest store additions in pharma retail in a single financial year. The company also launched new retail format 'All Day Stores', appointed Akshay Kumar as brand ambassador for UGO Generic, and completed a ₹350 crore QIP.

Likely market impact

The strong 84% revenue growth and margin expansion indicate improving operational efficiency. The rapid store expansion strategy and new initiatives like UGO Generic and All Day Stores position the company for continued growth, though investors should monitor integration of the fast-expanding retail network.